El Segundo undergoes Vet Biotechnology (VBT) Stem Cell Therapy

Stem cell processing started today for Australasia’s reigning weight for age champion El Segundo by Vet Biotechnology (VBT), Australia’s only regulated and licensed stem cell therapy company. The winner of more than $3.7m in prizemoney, El Segundo has a superficial digital flexor tendon injury (core lesion). Trainer Colin Little and veterinarian Dr John van Veenendaal of the Flemington Equine Clinic agreed that VBT’s stem cell tendon regeneration offered the best chance of a successful return to competition.

Vet Biotechnology’s autologous stem cell processing will reach double figures for the first time this month. General manager David Bridgland said that at the current rate, the Jan. figure might reach processing for the treatment of as many as 15 individual horses.

“The decision made by the directors of Vet Biotechnology to license this patented therapy from the inventors at the Royal Veterinary College, London, has proven to be a good one,” Mr Bridgland said. “This therapy has made a significant contribution to the retention of horses with formerly career-ending tendon and ligament injuries within our racing industry.”

The therapy involves the purification and expansion of bone-marrow derived mesenchymal stem cells into therapeutic doses of more than 4 million per ml for implantation to injured equine tendons and ligaments.

Mr Bridgland said VBT success stories include Pinions, Viz Vitae, High Cee, Valedictum, Accumulate, Tayashi Girl, Pantani, Taisho, and harness horses Speed Monster and Hayton Again among just a few of the first VBT stem cell recipients now post-rehabilitation. The average prizemoney return for treated horses stands at $4,449 per race start, thereby also providing commercial justification for the therapy.

VBT now eagerly awaits the next wave of treated racehorses returning to competition at Autumn Carnivals throughout Australia in 2008. El Segundo is likely to return for a light post-rehabilitation preparation next spring.

For further information, contact:
Peter Le Messurier
Chairman
Vet Biotechnology Ltd
ACN 105 577 017
Web page: www.vetbiotechnology.com.au
Ends...

Vet Biotechnology Ltd
(ACN 105 577 017)
(NSX codes VBL, VBLO)
MEDIA RELEASE Tuesday January 22, 2008 at 15.30 EST.